DERM logo

JOURNEY MEDICAL CORP

DERMNASDAQ
πŸ† #3780 by market capEarnings Nov 11US Equity
$5.10β–² $0.13 (+2.62%)
Pre-market Β· at close
πŸ””
Track DERM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.6%
7dβ–Ό 0.2%
14dβ–Ό 0.5%
30dβ–Ό 21.5%
ytdβ–Ό 33.8%
1yβ–Ό 35.5%
🏦Market Cap
$144M
Small Cap
πŸ“ˆRevenue Growth (YoY)
10.2%
Healthy
πŸ“ŠGross Margin
62.2%
High
πŸ’΅FCF Margin
-11.0%
Thin
βš–οΈP/S Ratio
2.1x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$4.90 – $5.10
52-Week Range
$4.31 – $9.56
Volume (shares)
6,104
Avg Volume (shares)
β€”
Shares Outstanding
28.2M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$62M
Last Q Revenue
$19M
P/E Ratio
-22.7
P/S Ratio
2.1x
EPS (TTM)
$-0.22
Dividend Yield
0.00%
Dilution (1yr)
+10.6%
DERM logo

JOURNEY MEDICAL CORP

DERM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$62Mβ–² +10.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
59.3%β–Ό βˆ’5.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$8Mβ–Ό βˆ’40.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$12Mβ–Ό βˆ’48.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
24.5Mβ–² +10.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$1Mβ–² +$4M YoY
StockOtter Β· stockotter.space

About JOURNEY MEDICAL CORP

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.